Procter & Gamble reported fiscal second‑quarter 2026 results on January 22 2026, delivering net sales of $22.21 billion— a 1 % year‑over‑year increase that fell short of the consensus estimate of $22.29 billion to $22.36 billion. Diluted earnings per share were $1.78, slightly below the $1.86 consensus, while core earnings per share of $1.88 beat the $1.87 estimate by $0.01. The company lowered its diluted net EPS growth outlook to 1 %–6 % from the prior 3 %–9 % range, citing higher restructuring charges and tariff headwinds.
The revenue rise was driven by a 4 % organic increase in the Beauty segment, offset by a 4 % decline in Baby, Feminine & Family Care. Net sales in the prior fiscal Q2 2025 were $21.9 billion, so the current quarter’s $22.21 billion represents a modest 1 % lift. Core gross margin contracted 50 basis points year‑over‑year, largely due to a 120‑basis‑point unfavorable mix shift, 60 basis points of product reinvestments, and 60 basis points of higher tariff costs. These headwinds were partially offset by 160 basis points of gross‑productivity savings and 50 basis points of pricing benefits, leaving operating margin down 70 basis points.
Margin compression reflects a combination of pricing pressure and cost inflation. The unfavorable mix shift—moving sales toward lower‑margin categories—drove the 120‑basis‑point decline, while tariff costs added 60 basis points of pressure. The company’s investment in productivity savings and pricing power helped mitigate the impact, but the net effect was a 70‑basis‑point drop in operating margin. This compression signals that, while P&G maintains pricing power in high‑margin Beauty products, it faces challenges in its core consumer staples categories where volume and mix are more sensitive to macro‑economic conditions.
Management reiterated its fiscal 2026 guidance for organic sales growth of flat to 4 % and core EPS growth of flat to 4 %, but cut the diluted net EPS growth outlook to 1 %–6 %. CEO Shailesh Jejurikar emphasized that the company remains on track to meet full‑year targets despite the “softest quarter” of the fiscal year, and highlighted confidence in stronger second‑half performance driven by innovation and improved execution. CFO Andre Schulten noted that the quarter’s top‑line results reflect underlying market trends and base‑period dynamics, and that the company expects sequential improvements ahead.
Analysts reacted to the mixed results. While the core EPS beat expectations, the revenue miss and the downward adjustment to diluted EPS guidance tempered enthusiasm. Bank of America Securities raised its price target to $171 from $170, maintaining a Buy rating, and JPMorgan upgraded the stock from Neutral to Overweight with a target of $165. The market’s response was driven by the company’s reaffirmation of full‑year guidance and its focus on a long‑term “reinvention” strategy, balanced against concerns over revenue shortfall and one‑time restructuring charges.
In summary, Procter & Gamble’s fiscal Q2 2026 earnings show modest top‑line growth, a slight earnings miss on diluted EPS, and a narrowed guidance range due to restructuring costs. Segment performance highlights Beauty as a growth driver while Baby, Feminine & Family Care lagged. Margin compression underscores the impact of mix shifts and tariff costs, but productivity gains and pricing benefits provide some offset. Management’s confidence in the second half and its long‑term reinvention plan suggest a focus on resilience and future growth, while the market remains cautious about the short‑term revenue miss and cost‑related headwinds.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.